BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
2 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
3 Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuaillon E, van de Perre P, Pichler C, Denkinger CM, Easterbrook P. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis 2017;17:693. [PMID: 29143616 DOI: 10.1186/s12879-017-2776-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
4 Huang JF, Hsieh MY, Wei YJ, Hung JY, Huang HT, Huang CI, Yeh ML, Huang CF, Jang TY, Hsu PY, Liang PC, Dai CY, Lin ZY, Yu ML, Chuang WL. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). Hepatol Int 2021. [PMID: 34850326 DOI: 10.1007/s12072-021-10275-7] [Reference Citation Analysis]
5 Isoda H, Oeda S, Takamori A, Sato K, Okada M, Iwane S, Takahashi H, Anzai K, Eguchi Y, Fujimoto K. Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects. Intern Med 2020;59:169-74. [PMID: 31534084 DOI: 10.2169/internalmedicine.3248-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 García Deltoro M, Ricart Olmos C. Hepatitis C virus infection and new treatment strategies. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37 Suppl 1:15-9. [PMID: 31138418 DOI: 10.1016/S0213-005X(19)30177-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ, Yu ML. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep 2018;8:15058. [PMID: 30305682 DOI: 10.1038/s41598-018-33448-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Galli C, Julicher P, Plebani M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection. Clin Chem Lab Med 2018;56:880-8. [PMID: 29702484 DOI: 10.1515/cclm-2017-0754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
9 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
10 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
11 Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274 [DOI: 10.3748/wjg.v28.i2.263] [Reference Citation Analysis]
12 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu M, Plauzolles A, Chiche L, Bourlière M, Abravanel F. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. Journal of Hepatology 2018;68:595-7. [DOI: 10.1016/j.jhep.2017.09.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol 2021;36:2247-54. [PMID: 33624849 DOI: 10.1111/jgh.15469] [Reference Citation Analysis]
16 Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, Morsy KH, Hetta HF. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist. 2019;12:273-279. [PMID: 30774394 DOI: 10.2147/idr.s181638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
17 Lei JH, Gong X, Xiao XQ, Chen Z, Peng F. Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China. Arch Med Sci 2018;14:1055-60. [PMID: 30154888 DOI: 10.5114/aoms.2017.70664] [Reference Citation Analysis]
18 Mizuochi T, Takano T, Yanagi T, Ushijima K, Suzuki M, Miyoshi Y, Ito Y, Inui A, Tajiri H. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018;53:419-426. [PMID: 28567493 DOI: 10.1007/s00535-017-1351-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
19 Nagao Y, Kimura T, Nagao H. Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture. Biomed Rep 2021;14:23. [PMID: 33335729 DOI: 10.3892/br.2020.1399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Enache EL, Sin A, Enache LS, Bancu L. Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. J Mol Diagn 2017;19:857-69. [PMID: 28860020 DOI: 10.1016/j.jmoldx.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 De Weggheleire A, De Baetselier I, An S, Goletti S, Suin V, Thai S, Francque S, Crucitti T, Lynen L, Van Gucht S, Kabamba BM. Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia. Infect Dis Ther 2020;9:657-67. [PMID: 32474893 DOI: 10.1007/s40121-020-00304-7] [Reference Citation Analysis]
22 Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118:556-64. [PMID: 30527566 DOI: 10.1016/j.jfma.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
23 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
24 Tian T, Wang J, Huang P, Li J, Yu R, Fan H, Xia X, Han Y, Zhang Y, Yue M. Genetic variations in NF-κB were associated with the susceptibility to hepatitis C virus infection among Chinese high-risk population. Sci Rep 2018;8:104. [PMID: 29311624 DOI: 10.1038/s41598-017-18463-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Reference Citation Analysis]
27 Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study. PLoS One 2019;14:e0224459. [PMID: 31661525 DOI: 10.1371/journal.pone.0224459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Inoue T, Hmwe SS, Shimada N, Kato K, Ide T, Torimura T, Kumada T, Toyoda H, Tsubota A, Takaguchi K, Wakita T, Tanaka Y. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS One 2017;12:e0170667. [PMID: 28118381 DOI: 10.1371/journal.pone.0170667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Parikh ND, Fu S, Rao H, Yang M, Li Y, Powell C, Wu E, Lin A, Xing B, Wei L, Lok ASF. Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. Dig Dis Sci 2017;62:3243-53. [PMID: 28948495 DOI: 10.1007/s10620-017-4776-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zang F, Yue M, Yao Y, Liu M, Fan H, Feng Y, Xia X, Huang P, Yu R. Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. Epidemiol Infect 2018;146:379-85. [PMID: 29271328 DOI: 10.1017/S0950268817002928] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
32 Hung HC, Liao HH, Chen SC, Tsao SM, Lee YT. Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis. Medicine (Baltimore) 2019;98:e15563. [PMID: 31083223 DOI: 10.1097/MD.0000000000015563] [Reference Citation Analysis]
33 Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel) 2021;11:2236. [PMID: 34943471 DOI: 10.3390/diagnostics11122236] [Reference Citation Analysis]
34 Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
35 Catlett B, Lamoury FMJ, Bajis S, Hajarizadeh B, Martinez D, Mowat Y, Cunningham PH, Jacka BP, Cloherty GA, Marks P, Dore GJ, Grebely J, Applegate TL. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. J Viral Hepat 2019;26:1423-30. [PMID: 31448470 DOI: 10.1111/jvh.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Thedja MD, Wibowo DP, El-Khobar KE, Ie SI, Setiawan L, Murti IS, Muljono DH; Turyadi. Improving Linkage to Care of Hepatitis C: Clinical Validation of GeneXpert® HCV Viral Load Point-of-Care Assay in Indonesia. Am J Trop Med Hyg 2021:tpmd201588. [PMID: 33999849 DOI: 10.4269/ajtmh.20-1588] [Reference Citation Analysis]
37 Örmeci N, Gülşen MT, Sezgin O, Aghayeva S, Demir M, Köksal I, Güner R, Erarslan E, Asiller ÖÖ, Balkan A, Yaraş S, Çalışkan Kartal A. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020;31:148-55. [PMID: 32141824 DOI: 10.5152/tjg.2020.19440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Sicras-Mainar A, Navarro-Artieda R, Sáez-Zafra M. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterol Hepatol 2018;41:234-44. [PMID: 29287992 DOI: 10.1016/j.gastrohep.2017.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
39 Malik F, Bailey H, Chan P, Collins IJ, Mozalevskis A, Thorne C, Easterbrook P. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. JHEP Rep 2021;3:100227. [PMID: 33665586 DOI: 10.1016/j.jhepr.2021.100227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
40 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
41 Tang L, Kamat M, Shukla A, Vora M, Kalal C, Kottilil S, Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis 2018;2018:9124604. [PMID: 30364048 DOI: 10.1155/2018/9124604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
42 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
43 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Reference Citation Analysis]
44 Skladany L, Janceková D, Svac J. Hepatitis C virus antibodies in outpatients with chronic kidney disease. Clin Exp Hepatol 2018;4:267-70. [PMID: 30603675 DOI: 10.5114/ceh.2018.80129] [Reference Citation Analysis]
45 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hepatol Int 2018;12:544-51. [PMID: 30426395 DOI: 10.1007/s12072-018-9908-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res 2021. [PMID: 34861090 DOI: 10.1111/hepr.13739] [Reference Citation Analysis]
47 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Nagao Y. The role of dentists in controlling hepatocellular carcinoma in Japan (Review). Exp Ther Med 2021;21:113. [PMID: 33335576 DOI: 10.3892/etm.2020.9545] [Reference Citation Analysis]
49 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
50 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
51 Wang CW, Liao KW, Chan CC, Yu ML, Chuang HY, Chiang HC, Huang PC. Association between urinary thiodiglycolic acid level and hepatic function or fibrosis index in school-aged children living near a petrochemical complex. Environ Pollut 2019;244:648-56. [PMID: 30384070 DOI: 10.1016/j.envpol.2018.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
52 Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol 2021;74:734-41. [PMID: 33248169 DOI: 10.1016/j.jhep.2020.11.027] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]
54 Aguilera A, Alados JC, Alonso R, Eiros JM, García F. Current position of viral load versus hepatitis C core antigen testing. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38 Suppl 1:12-8. [PMID: 32111360 DOI: 10.1016/j.eimc.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Dibba P, Cholankeril R, Li AA, Patel M, Fayek M, Dibble C, Okpara N, Hines A, Ahmed A. Hepatitis C in Pregnancy. Diseases 2018;6:E31. [PMID: 29702563 DOI: 10.3390/diseases6020031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]